Glenmark Pharmaceuticals Management
Management criteria checks 1/4
Glenmark Pharmaceuticals' CEO is Glenn Saldanha, appointed in Jan 2001, has a tenure of 23.83 years. total yearly compensation is ₹168.61M, comprised of 80% salary and 20% bonuses, including company stock and options. directly owns 0.35% of the company’s shares, worth ₹1.46B. The average tenure of the management team and the board of directors is 1.5 years and 6.5 years respectively.
Key information
Glenn Saldanha
Chief executive officer
₹168.6m
Total compensation
| CEO salary percentage | 80.0% |
| CEO tenure | 23.8yrs |
| CEO ownership | 0.4% |
| Management average tenure | 1.5yrs |
| Board average tenure | 6.5yrs |
Recent management updates
This Is Why Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation Looks Appropriate
Sep 21
Shareholders Will Probably Hold Off On Increasing Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation For The Time Being
Sep 23Recent updates
Pinning Down Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) P/S Is Difficult Right Now
Oct 26This Is Why Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation Looks Appropriate
Sep 21Glenmark Pharmaceuticals (NSE:GLENMARK) Is Paying Out A Dividend Of ₹2.50
Sep 06Calculating The Fair Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)
Aug 06Does Glenmark Pharmaceuticals (NSE:GLENMARK) Have A Healthy Balance Sheet?
Jun 16Is Glenmark Pharmaceuticals Limited (NSE:GLENMARK) Expensive For A Reason? A Look At Its Intrinsic Value
May 08Glenmark Pharmaceuticals (NSE:GLENMARK) Takes On Some Risk With Its Use Of Debt
Mar 09Is Glenmark Pharmaceuticals (NSE:GLENMARK) Using Too Much Debt?
Dec 07Shareholders Will Probably Hold Off On Increasing Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation For The Time Being
Sep 23Glenmark Pharmaceuticals (NSE:GLENMARK) Will Pay A Dividend Of ₹2.50
Sep 17Glenmark Pharmaceuticals (NSE:GLENMARK) Has Announced A Dividend Of ₹2.50
Aug 30A Look At The Intrinsic Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)
Aug 28We Think Glenmark Pharmaceuticals (NSE:GLENMARK) Is Taking Some Risk With Its Debt
Jul 03A Look At The Fair Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)
May 28Glenmark Pharmaceuticals (NSE:GLENMARK) Has A Somewhat Strained Balance Sheet
Mar 22Estimating The Fair Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)
Feb 14An Intrinsic Calculation For Glenmark Pharmaceuticals Limited (NSE:GLENMARK) Suggests It's 37% Undervalued
Oct 12Shareholders Will Probably Hold Off On Increasing Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation For The Time Being
Sep 21Glenmark Pharmaceuticals (NSE:GLENMARK) Has Announced A Dividend Of ₹2.50
Aug 29We Think Glenmark Pharmaceuticals (NSE:GLENMARK) Can Stay On Top Of Its Debt
Jun 20There May Be Reason For Hope In Glenmark Pharmaceuticals' (NSE:GLENMARK) Disappointing Earnings
Jun 04An Intrinsic Calculation For Glenmark Pharmaceuticals Limited (NSE:GLENMARK) Suggests It's 27% Undervalued
May 05If You Like EPS Growth Then Check Out Glenmark Pharmaceuticals (NSE:GLENMARK) Before It's Too Late
Mar 25CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -₹10b |
| Jun 30 2024 | n/a | n/a | -₹16b |
| Mar 31 2024 | ₹169m | ₹135m | -₹19b |
| Dec 31 2023 | n/a | n/a | -₹8b |
| Sep 30 2023 | n/a | n/a | -₹1b |
| Jun 30 2023 | n/a | n/a | ₹3b |
| Mar 31 2023 | ₹162m | ₹130m | -₹2b |
| Dec 31 2022 | n/a | n/a | ₹9b |
| Sep 30 2022 | n/a | n/a | ₹8b |
| Jun 30 2022 | n/a | n/a | ₹8b |
| Mar 31 2022 | ₹158m | ₹130m | ₹9b |
| Dec 31 2021 | n/a | n/a | ₹10b |
| Sep 30 2021 | n/a | n/a | ₹10b |
| Jun 30 2021 | n/a | n/a | ₹10b |
| Mar 31 2021 | ₹139m | ₹110m | ₹10b |
| Dec 31 2020 | n/a | n/a | ₹10b |
| Sep 30 2020 | n/a | n/a | ₹9b |
| Jun 30 2020 | n/a | n/a | ₹9b |
| Mar 31 2020 | ₹122m | ₹91m | ₹8b |
| Dec 31 2019 | n/a | n/a | ₹7b |
| Sep 30 2019 | n/a | n/a | ₹6b |
| Jun 30 2019 | n/a | n/a | ₹8b |
| Mar 31 2019 | ₹157m | ₹131m | ₹9b |
| Dec 31 2018 | n/a | n/a | ₹9b |
| Sep 30 2018 | n/a | n/a | ₹9b |
| Jun 30 2018 | n/a | n/a | ₹7b |
| Mar 31 2018 | ₹162m | ₹134m | ₹8b |
Compensation vs Market: Glenn's total compensation ($USD2.00M) is above average for companies of similar size in the Indian market ($USD776.72K).
Compensation vs Earnings: Glenn's compensation has increased whilst the company is unprofitable.
CEO
Glenn Saldanha (54 yo)
23.8yrs
Tenure
₹168,610,000
Compensation
Mr. Glenn Mario Saldanha has been the Managing Director and Chief Executive Officer of Glenmark Pharmaceuticals Limited since 2000. Mr. Saldanha serves as Chairman at Ichnos Sciences Inc. Mr. Saldanha serv...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman | 23.8yrs | ₹168.61m | 0.35% ₹ 1.5b | |
| Executive Director of Corporate Services & Executive Director | no data | ₹60.84m | 0.27% ₹ 1.1b | |
| Executive Director | less than a year | ₹102.12m | no data | |
| Company Secretary & Compliance Officer | 7.8yrs | ₹5.53m | no data | |
| President and Chief Human Resources Officer | 2.8yrs | no data | no data | |
| President & Head of Global Pharmaceutical Development | 2.2yrs | no data | no data | |
| President & Chief Quality Officer | 1.2yrs | no data | no data | |
| President & Global Head of Formulation Operations | 1.2yrs | no data | no data | |
| President & Business Head of India Formulations | 1.3yrs | no data | no data | |
| President and Business Head of Europe & Emerging Markets | 1.8yrs | no data | no data | |
| President & Business Head of North America | less than a year | no data | no data | |
| Investor Relations Officer | no data | no data | no data |
1.5yrs
Average Tenure
55yo
Average Age
Experienced Management: GLENMARK's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman | 26.1yrs | ₹168.61m | 0.35% ₹ 1.5b | |
| Executive Director of Corporate Services & Executive Director | 25.1yrs | ₹60.84m | 0.27% ₹ 1.1b | |
| Executive Director | 6.5yrs | ₹102.12m | no data | |
| President | less than a year | no data | no data | |
| Non Executive Director | 19.3yrs | ₹600.00k | 0.39% ₹ 1.6b | |
| Non-Executive Independent Director | 22.5yrs | ₹1.90m | 0.039% ₹ 160.1m | |
| Independent Non-Executive Director | 1.8yrs | ₹1.20m | no data | |
| Independent Non-Executive Director | 4.3yrs | ₹1.10m | no data | |
| Independent Non-Executive Director | 5.6yrs | ₹1.40m | no data |
6.5yrs
Average Tenure
61yo
Average Age
Experienced Board: GLENMARK's board of directors are considered experienced (6.5 years average tenure).